Novartis Ag

Other

Christian Mathes

Philipp Lustenberger

Martin Kesselgruber

Michael Foulkes

Gottfried Sedelmeier

Fabrice Gallou

Bernard Riss

Zhongbo Fei

Thierry Schlama

Qiangbiao Pan

Benli Zou

This invention relates to novel processes for synthesizing [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid and to intermediates that are used in such processes.

Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid

A catalytic process for the preparation of optically active compounds and their conversion thereafter to desired drug substances. In particular, the process relates to the preparation of (S)-3-(1-Dimethylamino-ethyl)-phenol using asymmetric catalytic reduction and transfer hydrogenation, thereby providing an improved route to forming drug substances such as rivastigimine and rivastigimine hydrogen tartrate.

Process for preparation of optically active compounds using transfer hydrogenation

Process for the preparation of optically active compounds using transfer hydrogenation

The invention relates to a process for the manufacture of a compound of formula: (Formula I); or a salt, especially a pharmaceutically acceptable salt with a base, thereof or a lactone thereof wherein the element (a) represents &#x2014;CH&#x2014;CH&#x2014; or &#x2014;CH&#x2550;CH&#x2014; and R represents a cyclic radical. 

Process for the manufacture of HMG-CoA reductase inhibitory mevalonic acid derivatives

Growing community of inventors

Offenburg, Germany

Christian Mathes